Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
Ivan Gentile, Maria Foggia, Maria Silvitelli, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 14

Showing 14 citing articles:

Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study
Ming Hong Choi, Eric Yuk Fai Wan, Ian C. K. Wong, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 11, pp. 1213-1224
Closed Access | Times Cited: 7
Efficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review
Caroline Hirsch, Nina Kreuzberger, Nicole Skoetz, et al.
Journal of Antimicrobial Chemotherapy (2025)
Open Access
Early initiation of combined therapy in severely immunocompromised patients with COVID-19: a retrospective cohort study
Salvatore Rotundo, Lavinia Berardelli, Sara Palma Gullì, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
Maike Janssen, Albrecht Leo, Cornelia Wolf, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 4, pp. 618-626
Open Access | Times Cited: 2
Re: Persistent COVID-19 in immunocompromised patients—Israeli Society of Infectious Diseases consensus statement on diagnosis and management by Meijer et al.
Alberto Enrico Maraolo, Nicola Schiano Moriello, Ivan Gentile
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 9, pp. 1209-1210
Closed Access | Times Cited: 2
Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis
Maria Mazzitelli, Alberto Enrico Maraolo, Claudia Cozzolino, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 2
Post COVID-19 Reflections and Questions: How Prepared Are We for the Next Pandemic?
George J. Kontoghiorghes, Annita Kolnagou, Christina Kontoghiorghe
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 859-859
Open Access | Times Cited: 1
Real‐Life Comparison of Antivirals for SARS‐CoV‐2 Omicron Infection in Patients With Hematologic Malignancies
Tommaso Francesco Aiello, Olivier Peyrony, Mariana Chumbita, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 3
Open Access | Times Cited: 1
Extended remdesivir administration in haematological patients with malignancies and COVID-19 during the Omicron era: safety and outcomes
Emmanuelle Gras, Tommaso Francesco Aiello, Mariana Chumbita, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 9, pp. 2364-2368
Closed Access | Times Cited: 1
Prevalencia y factores de riesgo en inmunodeprimidos asociados a infección por covid-19
Javier Martín Reyes-Baque, Bryan Steeven Bazurto-Acuña, Allyson Melissa García- Soledispa
MQRInvestigar (2024) Vol. 8, Iss. 3, pp. 2139-2157
Open Access | Times Cited: 1
Antiviral combination treatment strategies for SARS-CoV-2 infection in immunocompromised patients
Chiara Sepulcri, Claudia Bartalucci, Małgorzata Mikulska
Current Opinion in Infectious Diseases (2024) Vol. 37, Iss. 6, pp. 506-517
Closed Access | Times Cited: 1
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center study.
Ivan Gentile, Giulio Viceconte, F. M. Cuccurullo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Coronavirus Disease 2019 and Emerging Lung Infections in the Immunocompromised Patient
Catia Cillóniz, Antoni Torres
Clinics in Chest Medicine (2024) Vol. 46, Iss. 1, pp. 203-216
Closed Access
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study
Ivan Gentile, Giulio Viceconte, F. M. Cuccurullo, et al.
Annals of Medicine (2024) Vol. 57, Iss. 1
Open Access
Page 1

Scroll to top